A new Periodic Transaction Report filed with the U.S. House of Representatives shows Rep. Julia Letlow purchased shares of AbbVie Inc. (ABBV) common stock on April 28, 2025. The transaction was made personally by the member of Congress, not through a spouse or dependent, and is valued in the disclosed range of $1,001 to $15,000. The holding is reported through a Merrill Lynch Investment Account (#025).
Our internal signal classification tags this filing as a straightforward congress buy — a member of Congress adding to a position in a publicly traded company, disclosed through the routine mechanism required by the STOCK Act.
A Notable Timing Gap
The report was filed 105 days after the transaction date, well beyond the 45-day window the STOCK Act requires for disclosure of trades made by members of Congress. The filing does not include an explanation for the delay, and none is speculated here — the record simply shows the gap between the April 28 purchase and the eventual public disclosure.
Late filings under the STOCK Act are not uncommon and, on their own, are not evidence of wrongdoing. The law requires timely disclosure so the public can track potential conflicts of interest, but enforcement around the 45-day deadline has been inconsistent across Congress, a fact that regularly comes up in broader debates over whether lawmakers should be allowed to trade individual stocks at all.
This is not the first AbbVie-related filing from Letlow’s office that has drawn attention for its timing. Earlier disclosures showed the same lawmaker selling ABBV shares, in a report that was filed 199 days late. Taken together, the two filings show a pattern of both buying and selling the same healthcare stock, with disclosure delays attached to each transaction.
AbbVie is a large pharmaceutical company known for products including Humira and Skyrizi, and its shares are widely held across institutional and individual portfolios, including many retirement and brokerage accounts unrelated to any congressional activity. The purchase disclosed here represents one entry in a much larger set of transactions Letlow has reported over time through her Merrill Lynch account.
Periodic Transaction Reports like this one are a matter of public record, intended to let voters and watchdogs see when lawmakers buy or sell individual securities. They do not indicate investment advice, insider knowledge, or any judgment about the underlying company. As with all STOCK Act filings tracked on this site, the purpose here is to report what was disclosed, when it was disclosed, and how that timing compares to the law’s requirements — nothing more.